Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Pfizer R&D Japan G.K. (Japan)
Homepage:
pfizer.co.jp
Alternate names:
Pfizer R&D Japan G.K.,
ファイザーR&D合同会社
ROR:
048q44s16
OpenAlex ID:
I4405275768
Works
87
Awards
1
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
2022
·
Keiko Imamura
, Yuishin Izumi
, et al.
·
EClinicalMedicine
·
54
PDF
Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients
2019
·
Keiko Imamura
, Yuishin Izumi
, et al.
·
BMJ Open
·
50
PDF
Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer
2021
·
Hidetaka Suzuki
, Shuichi Mitsunaga
, et al.
·
Cancers
·
41
PDF
Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study
2019
·
Manabu Akazawa
, Wataru Mimura
, et al.
·
Journal of Pain Research
·
36
PDF
Validation of novel identification algorithms for major adverse cardiovascular events in a Japanese claims database
2020
·
Daisuke Shima
, Yoichi Ii
, et al.
·
Journal of Clinical Hypertension
·
32
PDF
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
2021
·
Miwa Haranaka
, James Baber
, et al.
·
Nature Communications
·
28
PDF
Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study
2021
·
Chikako Shirai
, Nobushige Matsuoka
, et al.
·
BMC Ophthalmology
·
25
PDF
Changes in Prescription of Psychotropic Drugs After Introduction of Polypharmacy Reduction Policy in Japan Based on a Large-Scale Claims Database
2019
·
Yoko Hirano
, Yoichi Ii
·
Clinical Drug Investigation
·
23
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3
2024
·
Shinsuke Iida
, Satoshi Ito
, et al.
·
Japanese Journal of Clinical Oncology
·
17
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
2021
·
Charles Chuah
, Liang Piu Koh
, et al.
·
International Journal of Hematology
·
16
Impact of genetically modified organism requirements on gene therapy development in the EU, Japan, and the US
2022
·
Gentaro Tajima
, Seoan Huh
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
15
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
2020
·
Masayuki Hino
, Itaru Matsumura
, et al.
·
International Journal of Hematology
·
15
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study
2024
·
Keiko Imamura
, Yuishin Izumi
, et al.
·
BMJ Open
·
13
PDF
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance
2023
·
Masataka Kuwana
, Naonobu Sugiyama
, et al.
·
Modern Rheumatology
·
13
PDF
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance
2019
·
Hiromi Yamaguchi
, Akira Shimatsu
, et al.
·
Endocrine Journal
·
11
PDF
Effectiveness of pregabalin for treatment of chronic cervical radiculopathy with upper limb radiating pain: an 8-week, multicenter prospective observational study in Japanese primary care settings
2019
·
Toshihiko Taguchi
, Kazutaka Nozawa
, et al.
·
Journal of Pain Research
·
11
PDF
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
2022
·
Takaaki Ono
, Masayuki Hino
, et al.
·
International Journal of Hematology
·
10
PDF
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults
2019
·
Megumi Inoue
, Takuma Yonemura
, et al.
·
Vaccine
·
10
The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain
2019
·
Bruce Parsons
, Koichi Fujii
, et al.
·
Journal of Pain Research
·
10
PDF
The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily
2009
·
T Fujiwara
, Y Ii
, et al.
·
Journal of Human Hypertension
·
10
Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study
2025
·
Masataka Kuwana
, Naonobu Sugiyama
, et al.
·
Modern Rheumatology
·
9
Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance
2020
·
Tomonori Ishii
, Yoko Hirano
, et al.
·
Clinical Therapeutics
·
9
PDF
Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
2019
·
Naohito Fujishima
, Toshiki Uchida
, et al.
·
International Journal of Hematology
·
9
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
2022
·
Naoto Takahashi
, Jorge E. Cortes
, et al.
·
International Journal of Hematology
·
8
Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study
2020
·
Shigeru Sugiyama
, Kazuo Sato
, et al.
·
Japanese Journal of Clinical Oncology
·
8
PDF
Show more works
View as search
Works count:
87
Citation count:
1,089
Year
Topic
Type
